Here are 1-3 brief analogies for Scienture (SCNX):

• Like a specialty pharmaceutical company such as Vertex Pharmaceuticals, but with an integrated layer of patient services to optimize the entire prescription journey.
• Imagine Gilead Sciences for targeted specialty drugs, but offering more robust patient engagement and navigation support.
• It's like Moderna creating innovative therapies for niche health needs, combined with dedicated support to guide patients through their treatment access and adherence.

• Specialty Pharmaceutical Products: Scienture acquires, develops, and distributes novel specialty medications addressing unmet market needs for patients and caregivers.
• Patient Engagement and Support Services: The company provides services to optimize the patient prescription journey, including adherence programs, financial assistance, and education to enhance patient outcomes.
• Specialty Pharmacy Fulfillment: Scienture offers comprehensive pharmacy services for the dispensing and delivery of complex specialty medications to patients.

Scienture Holdings, Inc. (SCNX) is a pharmaceutical product and health services company. Companies in the pharmaceutical sector typically distribute their products through a network of other businesses within the healthcare supply chain rather than selling directly to individual patients. Therefore, Scienture's major customers are primarily other companies.

Based on its business model as a pharmaceutical product company, Scienture's major customers are likely large pharmaceutical wholesalers and distributors, who then supply pharmacies, hospitals, and other healthcare providers across the U.S.

Major potential customers in this category include:

• McKesson Corporation (MCK)
• AmerisourceBergen Corporation (ABC)
• Cardinal Health, Inc. (CAH)

These companies are crucial intermediaries for pharmaceutical manufacturers, ensuring widespread distribution of products to the ultimate points of care.

Shankar Hariharan, Ph.D. Executive Chairman and Co-CEO

Dr. Shankar Hariharan is the Founder, President, and CEO of Scienture, Inc. prior to its merger with Scienture Holdings, Inc. in July 2024. He possesses over 35 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses, having held leadership positions at Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. As Executive Vice President and Chief Scientific Officer at Amneal, he oversaw Global Research and Development, Global Regulatory Affairs, and Specialty Product Development, and was instrumental in achieving significant revenue growth. His career includes involvement with the development and launch of notable brand products such as Celexa®, Lexapro®, Namenda®, and Megace ES®. Dr. Hariharan currently serves on the Board of Depymed, Inc. and the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.

Narasimhan Mani, Ph.D., MBA President and Co-CEO

Dr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He previously served as President & CEO for Kesin Pharma Corporation, a specialty pharmaceutical company, and as CEO of Xiromed LLC, a generics and specialty drug product company. His past roles also include Vice President of Global Corporate Strategy and Business Development at Amneal Pharmaceuticals, where he led strategic initiatives across global strategy, portfolio management, business development, and commercial operations. Dr. Mani has been instrumental in the launches of products like Ritalin® and Namenda XR®.

Eric Sherb Chief Financial Officer

Eric Sherb was appointed Chief Financial Officer of Scienture Holdings, Inc. in March 2025. He had been a consultant for the company since 2023. Mr. Sherb brings over 16 years of experience in accounting and finance, including expertise in financial reporting for public companies. He controls EMS Consulting Services, Inc., with which Scienture Holdings entered into an agreement for his services.

Prashant Patel President & Chief Operating Officer, Scienture Holdings, Inc.

Prashant Patel, a registered pharmacist (R.Ph.), serves as the President & Chief Operating Officer of Scienture Holdings, Inc. Prior to Eric Sherb's appointment, he served as the interim CFO. His dual role highlights his comprehensive involvement in both the strategic leadership and the operational execution of the company.

Rahul Surana, Ph.D., MBA Executive Vice President & Chief Operating Officer, Scienture LLC

Dr. Rahul Surana is a seasoned business leader with over two decades of expertise in the healthcare and pharmaceutical industries, spanning corporate strategy, R&D, and business development. At Scienture, he has played a pivotal role in building a robust 505(b)(2) NDA portfolio for the U.S. market, focusing on cardiovascular and central nervous system diseases. He has been instrumental in managing operations, finance, IT, and human resources, and in raising funds through seed rounds, convertible notes, and licensing deals.

The key risks to Scienture (SCNX) are:

1. Financial Distress and Going Concern Risk: Scienture is facing significant financial challenges, including substantial operating losses, negative cash flow, and a working capital deficit. The company's Altman Z-Score indicates financial distress and a potential risk of bankruptcy within the next two years. It has also a low cash balance and is dependent on its ability to raise future funding to continue its operations. Additionally, Scienture has received a Nasdaq notice for failing to meet the minimum bid price requirement.
2. Commercial Execution Risk for New Products: Scienture has recently pivoted to a specialty pharmaceutical model with FDA-approved products, Arbli™ and REZENOPY®, scheduled for commercial launch. There is a significant risk associated with the successful execution of these product launches, including achieving market adoption, securing payer access and group purchasing agreements, and managing competition. The company's current high valuation is largely predicated on rapid sales growth from these products, and any failure to meet these commercial targets could lead to a substantial decrease in its share price.
3. Shareholder Dilution Risk: To finance its operations and new product launches, Scienture has historically relied on various funding mechanisms, including equity offerings and equity line drawdowns. This practice has led to significant dilution for existing shareholders in the past, and the ongoing need for capital raises the likelihood of further dilution, which could negatively impact the stock price.

Scienture Holdings, Inc. (SCNX) operates as a comprehensive health services and pharmaceutical product company, focusing on novel specialty products within the U.S. market. The addressable markets for its main products and services are as follows:

• TRxADE Platform: This proprietary web-based platform facilitates trade among healthcare buyers and sellers of pharmaceuticals, accessories, and services for U.S. independent pharmacies. Scienture targets 24,000 U.S. independent pharmacies with combined annual pharmaceutical purchases of $93 billion. The broader U.S. pharmaceutical industry, which includes these transactions, is valued at $330 billion annually.
• ARBLI (losartan potassium Oral Suspension): ARBLI is the first FDA-approved ready-to-use oral liquid formulation of losartan in the U.S. market, indicated for the treatment of hypertension, reduction of stroke risk in specific patients, and diabetic nephropathy. The U.S. losartan market is approximately $245 million annually, with 71 million prescriptions.
• REZENOPY (naloxone HCl nasal spray): REZENOPY is a high-strength naloxone nasal spray approved by the FDA for the emergency treatment of opioid overdose. The U.S. naloxone market has annual sales of approximately $154 million and a unit volume of 9.3 million.

• Commercialization and expanded market access of Arbli™: The company has reported significant commercial progress and expanded market access for Arbli™, its FDA-approved ready-to-use oral suspension of losartan potassium. The commencement of commercial sales for Arbli™ has been noted as a factor in the company's stock performance, indicating its potential as a revenue driver.
• Launch of new specialty pharmaceutical products, particularly REZENOPY™ naloxone nasal spray: Scienture has confirmed the upcoming launch of its high-strength REZENOPY™ naloxone nasal spray, expected in Q2 2026. The company has already secured multiple Group Purchasing Organization (GPO) deals for this product, which are crucial for market penetration and distribution.
• Advancement and potential commercialization of pipeline drug candidates: Scienture has a pipeline of product candidates, including SCN-102 for hypertension, SCN-104 for acute migraine headaches, SCN-106 as a thrombolytic agent, and SCN-107 for post-surgical analgesia. Successful progression through clinical development and eventual market approval of these novel specialty products designed to satisfy unmet market needs will contribute significantly to future revenue.
• Strategic partnerships to optimize prescription journey and patient engagement: Scienture is actively forming strategic partnerships, such as the collaboration with BlinkRx to expand access to liquid losartan. These partnerships are aligned with the company's focus on optimizing the prescription journey and patient engagement, which can lead to increased product adoption and broader market reach.

Share Issuance

• In August 2025, Scienture Holdings, Inc. announced a registered direct offering to sell 3,225,000 shares of common stock at $1.20 per share, anticipating gross proceeds of approximately $3.9 million.
• During July 2025, Scienture Holdings, Inc. approved a capital raise of up to $3 million by issuing shares at $1.59 each, having already received approximately $1.2 million from investors for 754,716 shares sold.
• In November 2025, stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of common shares available for issuance from 5,000,000 to 25,000,000.

Inbound Investments

• Institutional investors agreed to purchase 3,225,000 shares of common stock in a registered direct offering in August 2025, with expected gross proceeds of approximately $3.9 million.
• In July 2025, Scienture Holdings, Inc. received approximately $1.2 million from investors including BlueCap Ventures LLC, Jinal Sheth, Nimish Sheth, and Chintan Shah through the sale of common stock.
• An agreement in October 2025 with Arena Finance Markets and Arena Special Opportunities III led to the full repayment and conversion of outstanding secured convertible debentures into common stock.